Targeted therapy of colorectal cancer: Clinical experience with bevacizumab

Oncologist

Volumn 9, Issue SUPPL. 1, 2004, Pages 11-18

  Fernando, Nishan H ^a   Hurwitz, Herbert I ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Bevacizumab; Clinical trial; Colorectal cancer; Monoclonal antibodies; Vascular endothelial growth factor

Indexed keywords

ANGIOGENIC FACTOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; VASCULOTROPIN;

ABDOMINAL PAIN; ADVANCED CANCER; ANGIOGENESIS; BLEEDING; CANCER CHEMOTHERAPY; CANCER THERAPY; CHILL; CLINICAL TRIAL; COLORECTAL CANCER; CONFERENCE PAPER; DIARRHEA; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DRUG TARGETING; EPISTAXIS; FEVER; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HUMAN; HYPERTENSION; INFECTION; LEUKOPENIA; LUNG EMBOLISM; METASTASIS; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEINURIA; RASH; SIDE EFFECT; STOMATITIS; SURVIVAL TIME; THROMBOSIS; TUMOR GROWTH; WEIGHT REDUCTION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS; COLORECTAL NEOPLASMS; FORECASTING; HUMANS; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 2942535898     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.9-suppl_1-11     Document Type: Conference Paper

References (40)

1. Hamilton J, Grem J. Lower gastrointestinal tract cancer. In: Kirkwood JM, Lotze MT, Yasko JM, eds. Current Cancer Therapeutics, Third Edition. Philadelphia: Churchill Livingstone, Current Medicine Inc., 1998:156-160.
2. Midgley R, Kerr D. Colorectal cancer. Lancet 1999;353:391-399.
3. Wolmark N, Rockette H, Mamounas E et al. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Duke's B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol 1999;17:3553-3559.
4. de Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-2947.
5. Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000;355:1041-1047.
6. Bomer MM, Dietrich D, Stupp R et al. Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer. J Clin Oncol 2002;20:1759-1766.
7. Kliche KO, Kubsch K, Raida M et al. Chronomodulated chemotherapy in metastatic gastrointestinal cancer combining 5-FU and sodium folinate with oxaliplatin, irinotecan or gemcitabine: the Jena experience in 79 patients. J Cancer Res Clin Oncol 2002;128:516-524.
8. Kouroussis C, Souglakos J, Mavroudis D et al. Oxaliplatin with high-dose leucovorin and infusional 5-fluorouracil in irinotecan-pretreated patients with advanced colorectal cancer (ACC). Am J Clin Oncol 2002;25:627-631.
9. Leonard P, Seymour MT, James R et al. Phase II study of irinotecan with bolus and high dose infusional 5-FU and folinic acid (modified de Gramont) for first or second line treatment of advanced or metastatic colorectal cancer. Br J Cancer 2002;87:1216-1220.
10. Luppi G, Zanelli F, Di Stasi A et al. Folfox 2 regimen in heavily pretreated patients with advanced colorectal cancer. Tumori 2002;88:270-272.
11. Ferrara N. Vascular endothelial growth factor as a target for anticancer therapy. The Oncologist 2004;9(suppl 1):2-10.
12. Ferrara N. Role of vascular endothelial growth factor in the regulation of angiogenesis. Kidney Int 1999;56:794-814.
13. Lee JC, Chow NH, Wang ST et al. Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. Eur J Cancer 2000;36:748-753.
14. Frank RE, Saclarides TJ, Leurgans S et al. Tumor angiogenesis as a predictor of recurrence and survival in patients with node-negative colon cancer. Ann Surg 1995;222:695-699.
15. Choi HJ, Hyun MS, Jung GJ et al. Tumor angiogenesis as a prognostic predictor in colorectal carcinoma with special reference to mode of metastasis and recurrence. Oncology 1998;55:575-581.
16. Takahashi Y, Kitadai Y, Bucana CD et al. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 1995;55:3964-3968.
17. Warren RS, Yaun H, Matli MR. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest 1995;95:1789-1797.
18. Kondo Y, Arii S, Mori A et al. Enhancement of angiogenesis, tumor growth, and metastasis by transfection of vascular endothelial growth factor into LoVo human colon cancer cell line. Clin Cancer Res 2000;6:622-630.
19. Kumar H, Heer K, Lee PW et al. Preoperative serum vascular endothelial growth factor can predict stage in colorectal cancer. Clin Cancer Res 1998;4:1279-1285.
20. Chin KF, Greenman J, Gardiner E et al. Pre-operative serum vascular endothelial growth factor can select patients for adjuvant treatment after curative resection in colorectal cancer. Br J Cancer 2000;83:1425-1431.
21. Fernando NH, Hurwitz HI. Inhibition of vascular endothelial growth factor in the treatment of colorectal cancer. Semin Oncol 2003;30(supp 6):39-50.
22. Bergsland E, Dickler MN. Maximizing the potential of bevacizumab in cancer treatment. The Oncologist 2004;9(suppl 1):36-42.
23. Kim K, Li B, Houck K et al. The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors 1992;7:53-64.
24. Fairbrother WJ, Christinger HW, Cochran AG et al. Novel peptides selected to bind vascular endothelial growth factor target the receptor-binding site. Biochemistry 1998;37:17754-17764.
25. Lin P, Sankar S, Shan S et al. Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor. Cell Growth Differ 1998;9:49-58.
26. Mendel DB, Laird AD, Smolich BD et al. Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent. Anticancer Drug Des 2000;15:29-41.
27. Pavco PA, Bouhana KS, Gallegos AM et al. Antitumor and antimetastatic activity of ribozymes targeting the messenger RNA of vascular endothelial growth factor receptors. Clin Cancer Res 2000;6:2094-2103.
28. Hunt S. Technology evaluation: IMC-1C11, ImClone Systems. Curr Opin Mol Ther 2001;3:418-424.
29. Kim KJ, Li B, Winer J et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993;362:841-844.
30. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-1186.
31. Gordon M, Margolin K, Talpaz M et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001;19:843-850.
32. Margolin K, Gordon MS, Holmgren E et al. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J Clin Oncol 2001;19:851-856.
33. Kabbinavar F, Hurwitz H, Fehrenbacher L et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003;21:60-65.
34. Giantonio BJ, Levy D, Catalano PJ et al. Incorporating angiogenesis inhibition with bevacizumab (anti-VEGF) into frontline chemotherapy with irinotecan (CPT-11), fluorouracil and leucovorin (FU/LV) for advanced colorectal cancer (AdvCRC): a toxicity analysis of ECOG study E2200. Proc Am Soc Clin Oncol 2002;21:126a.
35. Langmuir V, Cobleigh M, Herbst R et al. Successful longterm therapy with bevacizumab (Avastin™) in solid tumors: preliminary report on extension study AVF0778g. Proc Am Soc Clin Oncol 2002;21:32.
36. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin for the treatment of metastatic colorectal cancer: results of a randomized phase III trial. N Engl J Med 2004 (in press).
37. Benson AB, Catalano PJ, Meropol NJ et al. Bevacizumab (anti-VEGF) plus FOLFOX4 in previously treated advanced colorectal cancer (advCRC): an interim toxicity analysis of the Eastern Cooperative Oncology Group (ECOG) study E3200. Proc Am Soc Clin Oncol 2003;22:243.
38. Kabbinavar F, Wong J, Ayala R et al. The effect of antibody to vascular endothelial growth factor and cisplatin on the growth of lung tumors in nude mice. Proc Am Assoc Cancer Res 1995;36:488.
39. Borgstrom P, Gold DP, Hillan KJ et al. Importance of VEGF for breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin. Anticancer Res 1999;19:4203-4214.
40. Lee CG, Heijn M, di Tomaso E et al. Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 2000;60:5565-5570.